Celgene (NASDAQ:CELG) received a $112.00 price target from stock analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 6.85% from the stock’s current price.

The analysts wrote, “The Wall Street Journal (WSJ) has reported that CELG is in talks to buy JUNO (NC), or rather the 90% of the company that CELG does not already own.””

A number of other brokerages also recently weighed in on CELG. Royal Bank of Canada restated a “buy” rating and set a $173.00 target price on shares of Celgene in a report on Thursday, October 5th. Morgan Stanley downgraded shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a report on Thursday, October 5th. Robert W. Baird reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene in a report on Thursday, September 21st. Vetr upgraded shares of Celgene from a “hold” rating to a “buy” rating and set a $146.58 price objective on the stock in a report on Friday, October 6th. Finally, Zacks Investment Research downgraded shares of Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have given a buy rating to the company’s stock. Celgene presently has an average rating of “Buy” and an average target price of $131.18.

Shares of Celgene (NASDAQ:CELG) traded down $1.18 on Wednesday, reaching $104.82. 6,253,100 shares of the company were exchanged, compared to its average volume of 7,614,960. The firm has a market capitalization of $80,700.00, a P/E ratio of 24.72, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77. Celgene has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.58 earnings per share. analysts predict that Celgene will post 6.69 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. Capital Counsel LLC NY boosted its position in shares of Celgene by 0.4% in the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 6 shares during the period. Fort Pitt Capital Group LLC lifted its position in Celgene by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 11 shares during the period. Savant Capital LLC lifted its position in Celgene by 0.9% during the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 20 shares during the period. TCI Wealth Advisors Inc. lifted its position in Celgene by 0.9% during the second quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock worth $395,000 after purchasing an additional 26 shares during the period. Finally, Granite Investment Advisors LLC lifted its position in Celgene by 1.1% during the second quarter. Granite Investment Advisors LLC now owns 2,579 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 29 shares during the period. 79.85% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Cantor Fitzgerald Reiterates $112.00 Price Target for Celgene (CELG)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/01/17/celgene-celg-given-a-112-00-price-target-at-cantor-fitzgerald.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.